Hormone receptors in defining breast cancer prognosis—time for a rethink?
Valerie Speirs* and Abeer M Shaaban
Correspondence *Leeds Institute of Molecular Medicine, Wellcome Trust Brenner Building, St James's University Hospital, Beckett Street, Leeds LS9 7TK, UK
Email v.speirs@leeds.ac.uk
ER
and ER
are structurally and functionally distinct, but currently only ER is used to guide clinicians. The authors of this Viewpoint discuss whether this strategy is sufficiently informative, and how outcome and tumor response to adjuvant hormonal therapy can be followed more effectively.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.